Plerixafor
Generic name
Plerixafor
Brand name
ATC Code
L03AX16
- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
No information is present at this moment.
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
Available formulations
No information is present at this moment.
Dosages
| Mobilization of stem cells |
|---|
|
Renal impaiment in children > 3 months
Adjustment in renal impairment as specified:
GFR 50-80 ml/min/1.73 m2
Dose adjustment not neededGFR 30-50 ml/min/1.73 m2
67 percentage of single dose and dosing interval : 24 uurGFR 10-30 ml/min/1.73 m2
67 percentage of single dose and dosing interval : 24 uurGFR < 10 ml/min/1.73 m2
A general recommendation is not providedClinical consequences
With impaired renal function, the AUC of plerixafor increases and the half-life is prolonged. As a result, the risk of adverse reactions is increased.
Clinical implications:
In a study with adult volunteers, the AUC of plerixafor increased by 7% at creatinine clearance 51-80 ml/min, 34% at creatinine clearance 31-50 ml/min, and 38% at creatinine clearance ≤ 30 ml/min. Cmax was not affected by renal function.[MacFarland 2010]
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
Side effects in children do not differ from adults.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions
No information available on specific warnings and precautions in children.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
IMMUNOSTIMULANTS
This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.
| Colony stimulating factors | ||
|---|---|---|
| L03AA02 | ||
| L03AA14 | ||
| Interferons | ||
|---|---|---|
| L03AB05 | ||
| L03AB11 | ||
| L03AB10 | ||
| Other immunostimulants | ||
|---|---|---|
| L03AX13 | ||
| L03AX15 | ||
References
- Genzyme Europe BV, SmPC Mozobil (EU/1/09/537/001) 02-09-2019
- NKFK Werkgroep nierfunctiestoornissen, Extrapolatie van KNMP risico analyse "Verminderde nierfunctie" voor volwassenen naar kinderen, 20 Dec 2021
- MacFarland R., A pharmacokinetic study of plerixafor in subjects with varying degrees of renal impairment., Biol Blood Marrow Transplant, 2010, 16, 95-101
Changes
Therapeutic Drug Monitoring
Overdose
